Journal article
Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD
Nordic Bioscience Clinical Development, Herlev, Denmark; Nordic Bioscience, Herlev, Denmark. Electronic address: abi@nordicbioscience.com.1
Nordic Bioscience, Herlev, Denmark.2
Grünenthal, Aachen, Germany.3
Nordic Bioscience Clinical Development, Herlev, Denmark.4
Section of Respiratory Medicine, Hvidovre Hospital and Institute of Public Health, Copenhagen University, Copenhagen, Denmark.5
Respiratory and Allergy Research Group, Manchester Academic Science Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, England.6
Despite massive investments in the development of novel treatments for heterogeneous diseases such as COPD, the resources spent have only benefited a fraction of the population treated. Personalized health care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution.
This review discusses past successes and failures in drug development and biomarker research in COPD, describes research in COPD phenotypes and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression, and examines the role of extracellular matrix proteins found to be upregulated in COPD.
Novel biomarkers of connective tissue remodeling that may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacologic intervention are discussed.
| Language: | English |
|---|---|
| Year: | 2015 |
| Pages: | 16-23 |
| ISSN: | 19313543 and 00123692 |
| Types: | Journal article |
| DOI: | 10.1378/chest.15-0296 |
